piperidines has been researched along with 4-fluorofentanyl* in 4 studies
4 other study(ies) available for piperidines and 4-fluorofentanyl
Article | Year |
---|---|
Notes from the Field: Increased Incidence of Fentanyl-Related Deaths Involving Para-fluorofentanyl or Metonitazene - Knox County, Tennessee, November 2020-August 2021.
Topics: Benzimidazoles; Fentanyl; Humans; Illicit Drugs; Opiate Overdose; Piperidines; Tennessee | 2022 |
The identification and analytical characterization of 2,2'-difluorofentanyl.
New psychoactive substances (NPS) have expanded their distribution and become widely available in the global market in recent years. The illicit use of fentanyl and its analogs has become an important worldwide concern linked to their high potency and risk of fatal overdose. This study describes the analytical characterization of a new fentanyl derivative N-(1-(2-fluorophenethyl)-4-piperidinyl)-N-(2-fluorophenyl)propionamide (2,2'-difluorofentanyl). Identification was based on ultra-high-performance liquid chromatography-quadrupole time-of-flight-mass spectrometry (UHPLC-QTOF-MS), gas chromatography-mass spectrometry (GC-MS), Fourier transform infrared (FTIR) spectroscopy, and nuclear magnetic resonance (NMR) spectroscopy. To our knowledge, this study is the first to report on analytical data for this compound. The most abundant fragment ion in the electrospray ionization (ESI) mass spectrum under collision-induced dissociation (CID) mode was formed by the cleavage between the piperidine ring and the N-phenyl-amide moiety of the protonated molecule. Two diagnostic ions in the electron ionization (EI) mass spectrum were formed by the loss of a tropylium ion (M-91), and by the degradation of the piperidine ring and dissociate of the COC Topics: Analgesics, Opioid; Chromatography, High Pressure Liquid; Designer Drugs; Fentanyl; Gas Chromatography-Mass Spectrometry; Halogenation; Magnetic Resonance Spectroscopy; Piperidines; Psychotropic Drugs; Spectrometry, Mass, Electrospray Ionization; Spectroscopy, Fourier Transform Infrared | 2018 |
Seizure of illicitly produced para-fluorofentanyl: quantitative analysis of the content of capsules and tablets.
A gas chromatography/mass spectrometry (GC/MS) method for the quantification of para-fluorofentanyl (pFF) in powder and powdered samples was developed and validated. The method was applied on a seizure of capsules and tablets, that had been confiscated at an illicit production site in the Netherlands. The investigated capsules and tablets contained pFF in the range of 33.8-408.7 microg. As caffeine was detected as being an adulterant, a HPLC/UV method for the quantification of caffeine in capsules and tablets was also validated and applied. Caffeine was detected in the range of 25.6-108 mg per capsule or tablet. Based on an extrapolation of pharmacological and toxicological data of fentanyl, it can be argued that the highest detected single dose of pFF could be lethal, when administered orally. However, the large variability of the doses observed for pFF could mislead abusers, potentially leading to multiple doses and thus overdosing. Topics: Caffeine; Capsules; Chromatography, High Pressure Liquid; Gas Chromatography-Mass Spectrometry; Illicit Drugs; Piperidines; Powders; Reproducibility of Results; Spectrophotometry, Ultraviolet; Tablets | 2003 |
Interaction of p-fluorofentanyl on cloned human opioid receptors and exploration of the role of Trp-318 and His-319 in mu-opioid receptor selectivity.
In this study, we investigated the interactions of p-fluorofentanyl, an opioid designer drug, fentanyl, sufentanyl, and morphine on cloned human mu-, kappa-, and delta-opioid receptors coexpressed with heteromultimeric G protein-coupled inwardly rectifying K(+) channels (GIRK1/GIRK2) and a regulator of G protein signaling (RGS4) in Xenopus oocytes. We demonstrate that p-fluorofentanyl more potently activates GIRK1/GIRK2 channels through opioid receptors than fentanyl and that the p-fluoro substitution also changes the potency profile from mu > kappa > delta (fentanyl) to mu > delta > or = kappa (p-fluorofentanyl). A comparison of ligand efficacy revealed that morphine, fentanyl, and its analogs less efficiently activate GIRK1/GIRK2 channels through human mu-opioid receptor than [D-Ala(2),N-Me-Phe(4),Gly(5)-ol]-enkephalin. Using site-directed mutagenesis, we investigated whether mutating residues Trp-318 and His-319 to their corresponding residues in kappa- and delta-opioid receptors provides the molecular basis for mu/delta selectivity and mu/kappa selectivity. Changes in EC(50) values for the W318L and W318Y/H319Y mu-opioid receptors show a partial contribution of these residues to the decreased GIRK1/GIRK2 channel activation by fentanyl analogs through kappa- and delta-opioid receptors. The most pronounced effect was observed for p-fluorofentanyl, suggesting that an interaction between the 4-fluorophenylpropanamide moiety of the drug and residues Trp-318 and His-319 is important for the resulting enhanced GIRK1/GIRK2 channel activation through the mu-opioid receptor. Finally, we demonstrate that mutation of W318L confers delta-like potency for morphine on the mutant mu-opioid receptor. Topics: Animals; Cloning, Molecular; Designer Drugs; Fentanyl; G Protein-Coupled Inwardly-Rectifying Potassium Channels; Histidine; Humans; Ligands; Morphine; Mutation; Narcotics; Oocytes; Patch-Clamp Techniques; Piperidines; Potassium Channels; Potassium Channels, Inwardly Rectifying; Receptors, Opioid, delta; Receptors, Opioid, kappa; Receptors, Opioid, mu; Sufentanil; Tryptophan; Xenopus laevis | 2000 |